WuXi XDC (2268.HK) - How Long Will the Rally Last?

- Wilson Sonsini, Davis Polk, Fangda, Jingtian on $470 mln WuXi XDC Hong Kong IPO | Asian Legal Business
PRC law firm Fangda Partners and U.S. law firm Wilson Sonsini Goodrich & Rosati have advised Chinese medical research group WuXi XDC on its...
from: | Asian Legal Business

- Chinese Biopharma Firm WuXi XDC Jumps 31% on Hong Kong Debut
(Bloomberg) — A Chinese maker of drugs used in cancer treatments surged in Hong Kong after pricing its IPO at the top of a marketed range,...
from: Caixin Global

- WuXi XDC (2268.HK) - How Long Will the Rally Last? - Xinyao (Criss) Wang
WuXi XDC's shares surged since IPO in "honeymoon period".Share price new highs are worth looking forward to unless the short-term logic is...
from: Smartkarma

- Wuxi XDC shares surge 31% in Hong Kong trading debut By Investing.com
HONG KONG - Wuxi XDC Cayman, a subsidiary of Wuxi Biologics specializing in cancer treatment development, saw its shares soar by 31% on its...
from: Investing.com

- China's WuXi XDC jumps 40% in Hong Kong trading debut
SYDNEY :Chinese medical research group WuXi XDC's shares have risen nearly 40 per cent as the stock started trading on the Hong Kong Stock...
from: CNA

- Chinese Biopharma Firm WuXi XDC Jumps 31% on Hong Kong Debut
(Bloomberg) — A Chinese maker of drugs used in cancer treatments surged in Hong Kong after pricing its IPO at the top of a marketed range,...
from: Caixin Global

- China's WuXi XDC jumps 40% in Hong Kong trading debut
SYDNEY :Chinese medical research group WuXi XDC's shares have risen nearly 40 per cent as the stock started trading on the Hong Kong Stock...
from: CNA

- Wuxi XDC shares surge 31% in Hong Kong trading debut By Investing.com
HONG KONG - Wuxi XDC Cayman, a subsidiary of Wuxi Biologics specializing in cancer treatment development, saw its shares soar by 31% on its...
from: Investing.com

China, Initial public offering, Stock, The Stock Exchange of Hong Kong Limited